Skip to main content
Press Release

GE completes acquisition of Thermo Fisher HyClone™

April 08, 2014

GE (NYSE:GE) announced today that it has completed the acquisition of Thermo Fisher's HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses. The acquisition allows GE to expand its offering of tools, technologies and services for the discovery and manufacture of innovative new medicines, vaccines and diagnostics in its growing Life Sciences business.

Commenting on the acquisition, Brian Hood, General Manager of GE Healthcare's A&NZ Life Sciences business was excited about the latest addition to the Life Sciences portfolio.

"GE Healthcare Life Sciences vision is to be considered a leading partner and thought leader in the development of a mature Research, Development and Biomanufacturing sector in Australia and New Zealand.

"We have been providing expertise and tools for research into cells & proteins, drug discovery research, as well as support for large-scale manufacturing of biopharmaceuticals for over 50 years.

"The acquisition of Thermo Fisher's HyClone™ cell culture media provides us with manufacturing centres of excellence located in Tauranga, New Zealand and Melbourne, employing over 27 skilled workers in advanced manufacturing, providing Cell Culture products to many of the world's leading pharmaceutical companies and academic institutes," he said.

business unit